Prevenzione primaria della malattia cardiovascolare: c’è bisogno di un’aspirina?
The efficacy of antiplatelet treatment with aspirin in the primary prevention of major cardiovascular events was questioned during 2018, following a new series of trials that we summarize here in a quick synoptic overview. The three studies involved are the ASPREE trial, the ASCEND study and the ARR...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
AboutScience Srl
2019-09-01
|
| Rangatū: | Giornale di Clinica Nefrologia e Dialisi |
| Urunga tuihono: | https://journals.aboutscience.eu/index.php/gcnd/article/view/535 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
